{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:47:25Z","timestamp":1793692045155,"version":"4.5.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novo Nordisk France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lower extremity peripheral artery disease (PAD) often results from atherosclerosis, and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). Individuals with T2DM exhibit a more severe manifestation and a more distal distribution of PAD compared to those without diabetes, adding complexity to the therapeutic management of PAD in this particular patient population. Indeed, the management of PAD in patients with T2DM requires a multidisciplinary and individualized approach that addresses both the systemic effects of diabetes and the specific vascular complications of PAD. Hence, cardiovascular prevention is of the utmost importance in patients with T2DM and PAD, and encompasses smoking cessation, a healthy diet, structured exercise, careful foot monitoring, and adherence to routine preventive treatments such as statins, antiplatelet agents, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. It is also recommended to incorporate glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in the medical management of patients with T2DM and PAD, due to their demonstrated cardiovascular benefits. However, the specific impact of these novel glucose-lowering agents for individuals with PAD remains obscured within the background of cardiovascular outcome trials (CVOTs). In this review article, we distil evidence, through a comprehensive literature search of CVOTs and clinical guidelines, to offer key directions for the optimal medical management of individuals with T2DM and lower extremity PAD in the era of GLP-1RA and SGLT2i.<\/jats:p>","DOI":"10.1186\/s12933-024-02325-9","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:02:41Z","timestamp":1719410561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review"],"prefix":"10.1186","volume":"23","author":[{"given":"Guillaume","family":"Mah\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mohammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Sarlon-Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Lan\u00e9elle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Mirault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Darmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"7","key":"2325_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/eurjpc\/zwad381","volume":"31","author":"C Adou","year":"2024","unstructured":"Adou C, Magne J, Gazere N, Aouida M, Chastaingt L, Aboyans V. Global epidemiology of lower extremity artery disease in the 21st century (2000\u20132021): a systematic review and meta-analysis. Eur J Prev Cardiol. 2024;31(7):803\u201311.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"2325_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","volume":"24","author":"EB Jude","year":"2001","unstructured":"Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24(8):1433\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"2325_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12933-016-0446-x","volume":"15","author":"K Mohammedi","year":"2016","unstructured":"Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. 2016;15(1):129.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"2325_CR4","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","volume":"144","author":"MH Criqui","year":"2021","unstructured":"Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation. 2021;144(9):e171\u201391.","journal-title":"Circulation"},{"issue":"3","key":"2325_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/ehjqcco\/qcaa095","volume":"8","author":"N Bhandari","year":"2022","unstructured":"Bhandari N, Newman JD, Berger JS, Smilowitz NR. Diabetes mellitus and outcomes of lower extremity revascularization for peripheral artery disease. Eur Heart J Qual Care Clin Outcomes. 2022;8(3):298\u2013306.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"1","key":"2325_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2337\/dc18-1380","volume":"42","author":"LS Geiss","year":"2019","unstructured":"Geiss LS, Li Y, Hora I, Albright A, Rolka D, Gregg EW. Resurgence of diabetes-related nontraumatic lower-extremity amputation in the young and middle-aged adult U.S. population. Diabetes Care. 2019;42(1):50\u20134.","journal-title":"Diabetes Care"},{"issue":"1","key":"2325_CR7","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.5435\/JAAOS-D-21-00293","volume":"30","author":"CC Stewart","year":"2022","unstructured":"Stewart CC, Berhaneselase E, Morshed S. The burden of patients with lower limb amputations in a community safety-net hospital. J Am Acad Orthop Surg. 2022;30(1):e59\u201366.","journal-title":"J Am Acad Orthop Surg"},{"issue":"10","key":"2325_CR8","doi-asserted-by":"publisher","first-page":"e1553","DOI":"10.1016\/S2214-109X(23)00355-8","volume":"11","author":"GBD 2019 Peripheral Artery Disease Collaborators","year":"2023","unstructured":"GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob Health. 2023;11(10):e1553\u201365.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"2325_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2325_CR10","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","volume":"40","author":"JA Barnes","year":"2020","unstructured":"Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(8):1808\u201317.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2325_CR11","first-page":"e726","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2017;135(12):e726\u201379.","journal-title":"Circulation"},{"issue":"9","key":"2325_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, Bj\u00f6rck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)the Task Force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763\u2013816.","journal-title":"Eur Heart J"},{"key":"2325_CR13","doi-asserted-by":"publisher","unstructured":"Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt CA et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev. 2023;40(3):e3686. https:\/\/doi.org\/10.1002\/dmrr.3686","DOI":"10.1002\/dmrr.3686"},{"issue":"7","key":"2325_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1111\/dom.15065","volume":"25","author":"TW Yi","year":"2023","unstructured":"Yi TW, Wong MMY, Neuen BL, Arnott C, Poirier P, Seufert J, et al. Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS program and CREDENCE trial. Diabetes Obes Metab. 2023;25(7):2043\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"2325_CR15","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehad276","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, et al. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023;44(24):2170\u201383.","journal-title":"Eur Heart J"},{"issue":"4","key":"2325_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137(4):405\u20137.","journal-title":"Circulation"},{"issue":"7","key":"2325_CR17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","volume":"24","author":"S Verma","year":"2022","unstructured":"Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24(7):1288\u201399.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2325_CR18","doi-asserted-by":"publisher","first-page":"e008018","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","volume":"12","author":"A Badjatiya","year":"2019","unstructured":"Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, et al. Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL Trial. Circ Cardiovasc Interv. 2019;12(12):e008018.","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"2325_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1055\/s-0038-1676094","volume":"35","author":"S Dhand","year":"2018","unstructured":"Dhand S. Multidisciplinary approach to PAD: Who\u2019s on your team? Semin Intervent Radiol. 2018;35(5):378\u201383.","journal-title":"Semin Intervent Radiol"},{"issue":"12","key":"2325_CR20","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.2337\/diacare.26.12.3333","volume":"26","author":"American Diabetes Association","year":"2003","unstructured":"American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26(12):3333\u201341.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2325_CR21","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179\u2013218.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2325_CR22","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S158\u201390.","journal-title":"Diabetes Care"},{"issue":"1","key":"2325_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13047-022-00550-7","volume":"15","author":"V Chuter","year":"2022","unstructured":"Chuter V, Quigley F, Tosenovsky P, Ritter JC, Charles J, Cheney J, et al. Australian guideline on diagnosis and management of peripheral artery disease: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. J Foot Ankle Res. 2022;15(1):51.","journal-title":"J Foot Ankle Res"},{"issue":"5","key":"2325_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cjca.2022.02.029","volume":"38","author":"BL Abramson","year":"2022","unstructured":"Abramson BL, Al-Omran M, Anand SS, Albalawi Z, Coutinho T, de Mestral C, et al. Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease. Can J Cardiol. 2022;38(5):560\u201387.","journal-title":"Can J Cardiol"},{"key":"2325_CR25","doi-asserted-by":"publisher","first-page":"tkaa017","DOI":"10.1093\/burnst\/tkaa017","volume":"8","author":"A Wang","year":"2020","unstructured":"Wang A, Lv G, Cheng X, Ma X, Wang W, Gui J, et al. Guidelines on multidisciplinary approaches for the prevention and management of diabetic foot disease (2020 edition). Burns Trauma. 2020;8:tkaa017.","journal-title":"Burns Trauma"},{"issue":"39","key":"2325_CR26","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"39","key":"2325_CR27","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"V Aboyans","year":"2021","unstructured":"Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42(39):4013\u201324.","journal-title":"Eur Heart J"},{"issue":"1","key":"2325_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","volume":"67","author":"J Nordanstig","year":"2024","unstructured":"Nordanstig J, Behrendt CA, Baumgartner I, Belch J, B\u00e4ck M, Fitridge R, et al. European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication. Eur J Vasc Endovasc Surg. 2024;67(1):9\u201396.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"S 01","key":"2325_CR29","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1055\/a-1018-9250","volume":"127","author":"B Balletshofer","year":"2019","unstructured":"Balletshofer B, Ito W, Lawall H, Malyar N, Oberl\u00e4nder Y, Reimer P, et al. Position paper on the diagnosis and treatment of peripheral arterial disease (PAD) in people with diabetes mellitus. Exp Clin Endocrinol Diabetes. 2019;127(S 01):S105\u201313.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"S 01","key":"2325_CR30","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1055\/a-1624-3631","volume":"130","author":"B Balletshofer","year":"2022","unstructured":"Balletshofer B, B\u00f6ckler D, Diener H, Heckenkamp J, Ito W, Katoh M, et al. Position paper on the diagnosis and treatment of peripheral arterial disease (PAD) in people with diabetes mellitus. Exp Clin Endocrinol Diabetes. 2022;130(S 01):S127\u201336.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2325_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.avsg.2020.11.011","volume":"72","author":"G Mah\u00e9","year":"2021","unstructured":"Mah\u00e9 G, Boge G, Bura-Rivi\u00e8re A, Chakf\u00e9 N, Constans J, Goueffic Y, et al. Disparities between international guidelines (AHA\/ESC\/ESVS\/ESVM\/SVS) concerning lower extremity arterial disease: consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). Ann Vasc Surg. 2021;72:1\u201356.","journal-title":"Ann Vasc Surg"},{"issue":"6","key":"2325_CR32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","volume":"62","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program. Diabetologia. 2019;62(6):926\u201338.","journal-title":"Diabetologia"},{"issue":"6","key":"2325_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.14671","volume":"24","author":"JY Barraclough","year":"2022","unstructured":"Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24(6):1072\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2325_CR34","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/dom.14091","volume":"22","author":"C Arnott","year":"2020","unstructured":"Arnott C, Huang Y, Neuen BL, Di Tanna GL, Cannon CP, Oh R, et al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab. 2020;22(10):1753\u201366.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2325_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","volume":"142","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, et al. Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734\u201347.","journal-title":"Circulation"},{"issue":"1","key":"2325_CR36","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(1):e4\u20135.","journal-title":"Diabetes Care"},{"issue":"15","key":"2325_CR37","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"2325_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"2325_CR39","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","volume":"25","author":"DZI Cherney","year":"2023","unstructured":"Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Powell DR, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes Obes Metab. 2023;25(6):1646\u201357.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2325_CR40","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.14513","volume":"23","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Ferrannini E, Umpierrez GE, Peters AL, Rosenstock J, Carroll AK, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metab. 2021;23(12):2632\u201342.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2325_CR41","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/dc18-1094","volume":"41","author":"K Dhatariya","year":"2018","unstructured":"Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care. 2018;41(10):2229\u201335.","journal-title":"Diabetes Care"},{"issue":"10","key":"2325_CR42","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.2337\/dc16-0588","volume":"39","author":"K Mohammedi","year":"2016","unstructured":"Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Williams B, Lisheng L, et al. Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diabetes Care. 2016;39(10):1796\u2013803.","journal-title":"Diabetes Care"},{"issue":"11","key":"2325_CR43","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1210\/jc.2019-00980","volume":"104","author":"GP Fadini","year":"2019","unstructured":"Fadini GP, Albiero M, Bonora BM, Avogaro A. Angiogenic abnormalities in diabetes mellitus: mechanistic and clinical aspects. J Clin Endocrinol Metab. 2019;104(11):5431\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2325_CR44","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41569-021-00663-9","volume":"19","author":"J Golledge","year":"2022","unstructured":"Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat Rev Cardiol. 2022;19(7):456\u201374.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2325_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12933-023-02056-3","volume":"22","author":"D Mauricio","year":"2023","unstructured":"Mauricio D, Gratac\u00f2s M, Franch-Nadal J. Diabetic microvascular disease in non-classical beds: the hidden impact beyond the retina, the kidney, and the peripheral nerves. Cardiovasc Diabetol. 2023;22(1):314.","journal-title":"Cardiovasc Diabetol"},{"issue":"31","key":"2325_CR46","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","volume":"34","author":"F Paneni","year":"2013","unstructured":"Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436\u201343.","journal-title":"Eur Heart J"},{"issue":"3","key":"2325_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327\u201334.","journal-title":"JAMA"},{"issue":"10","key":"2325_CR48","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.2337\/dc18-0695","volume":"41","author":"M Nativel","year":"2018","unstructured":"Nativel M, Schneider F, Saulnier PJ, Gand E, Ragot S, Meilhac O, et al. Prognostic values of inflammatory and redox status biomarkers on the risk of major lower-extremity artery disease in individuals with type 2 diabetes. Diabetes Care. 2018;41(10):2162\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"2325_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/1753-0407.13372","volume":"15","author":"H Deng","year":"2023","unstructured":"Deng H, Li B, Shen Q, Zhang C, Kuang L, Chen R, et al. Mechanisms of diabetic foot ulceration: a review. J Diabetes. 2023;15(4):299\u2013312.","journal-title":"J Diabetes"},{"key":"2325_CR50","doi-asserted-by":"publisher","first-page":"1093355","DOI":"10.3389\/fcvm.2023.1093355","volume":"10","author":"TI Kim","year":"2023","unstructured":"Kim TI, Guzman RJ. Medial artery calcification in peripheral artery disease. Front Cardiovasc Med. 2023;10:1093355.","journal-title":"Front Cardiovasc Med"},{"key":"2325_CR51","doi-asserted-by":"publisher","first-page":"742719","DOI":"10.1155\/2011\/742719","volume":"2011","author":"N Kakouros","year":"2011","unstructured":"Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol. 2011;2011:742719.","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2325_CR52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/j.semvascsurg.2012.04.005","volume":"25","author":"GW Gibbons","year":"2012","unstructured":"Gibbons GW, Shaw PM. Diabetic vascular disease: characteristics of vascular disease unique to the diabetic patient. Semin Vasc Surg. 2012;25(2):89\u201392.","journal-title":"Semin Vasc Surg"},{"issue":"3","key":"2325_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1464-5491.2010.03208.x","volume":"28","author":"G Mah\u00e9","year":"2011","unstructured":"Mah\u00e9 G, Ouedraogo N, Leftheriotis G, Vielle B, Picquet J, Abraham P. Exercise treadmill testing in patients with claudication, with and without diabetes. Diabet Med. 2011;28(3):356\u201362.","journal-title":"Diabet Med"},{"issue":"9","key":"2325_CR54","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1161\/ATVBAHA.121.316638","volume":"41","author":"C Mercier","year":"2021","unstructured":"Mercier C, Brazeau T, Lamoureux J, Boisvert E, Robillard S, Breton V, et al. Diabetes impaired ischemia-induced PDGF (platelet-derived growth factor) signaling actions and vessel formation through the activation of Scr homology 2-containing phosphatase-1. Arterioscler Thromb Vasc Biol. 2021;41(9):2469\u201382.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2325_CR55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/ATVBAHA.119.312859","volume":"40","author":"A Behroozian","year":"2020","unstructured":"Behroozian A, Beckman JA. Microvascular disease increases amputation in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(3):534\u201340.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2325_CR56","first-page":"167","volume":"27","author":"MS Lee","year":"2015","unstructured":"Lee MS, Rha SW, Han SK, Choi BG, Choi SY, Ali J, et al. Comparison of diabetic and non-diabetic patients undergoing endovascular revascularization for peripheral arterial disease. J Invasive Cardiol. 2015;27(3):167\u201371.","journal-title":"J Invasive Cardiol"},{"issue":"11","key":"2325_CR57","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.2337\/dc20-1085","volume":"43","author":"N Foussard","year":"2020","unstructured":"Foussard N, Saulnier PJ, Potier L, Ragot S, Schneider F, Gand E, et al. Relationship between diabetic retinopathy stages and risk of major lower-extremity arterial disease in patients with type 2 diabetes. Diabetes Care. 2020;43(11):2751\u20139.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2325_CR58","doi-asserted-by":"publisher","first-page":"e3276","DOI":"10.1002\/dmrr.3276","volume":"36","author":"RJ Hinchliffe","year":"2020","unstructured":"Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3276.","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"2325_CR59","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/dc16-1594","volume":"39","author":"K Mohammedi","year":"2016","unstructured":"Mohammedi K, Woodward M, Zoungas S, Li Q, Harrap S, Patel A, et al. Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes. Diabetes Care. 2016;39(12):2270\u20137.","journal-title":"Diabetes Care"},{"issue":"2","key":"2325_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40200-020-00594-1","volume":"19","author":"JE Trihan","year":"2020","unstructured":"Trihan JE, Lan\u00e9elle D, Metcalfe N, Perez Martin A, Frances P. Diabetes-associated dermatological manifestations in primary care and their association with vascular complications. J Diabetes Metab Disord. 2020;19(2):989\u201396.","journal-title":"J Diabetes Metab Disord"},{"issue":"1S","key":"2325_CR61","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","volume":"58","author":"MS Conte","year":"2019","unstructured":"Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1\u2013Se10933.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"2325_CR62","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jvs.2019.05.050","volume":"71","author":"AF AbuRahma","year":"2020","unstructured":"AbuRahma AF, Adams E, AbuRahma J, Mata LA, Dean LS, Caron C, et al. Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease. J Vasc Surg. 2020;71(3):937\u201345.","journal-title":"J Vasc Surg"},{"issue":"5","key":"2325_CR63","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1479164118782887","volume":"15","author":"PE Tehan","year":"2018","unstructured":"Tehan PE, Sebastian M, Barwick AL, Chuter VH. How sensitive and specific is continuous-wave doppler for detecting peripheral arterial disease in people with and without diabetes? A cross-sectional study. Diab Vasc Dis Res. 2018;15(5):396\u2013401.","journal-title":"Diab Vasc Dis Res"},{"key":"2325_CR64","doi-asserted-by":"publisher","first-page":"744354","DOI":"10.3389\/fcvm.2021.744354","volume":"8","author":"JE Trihan","year":"2021","unstructured":"Trihan JE, Mah\u00e9 G, Croquette M, Coutant V, Thollot C, Guillaumat J, et al. Accuracy of acceleration time of distal arteries to diagnose severe peripheral arterial disease. Front Cardiovasc Med. 2021;8:744354.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2325_CR65","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jama.2018.4250","volume":"320","author":"JM Guirguis-Blake","year":"2018","unstructured":"Guirguis-Blake JM, Evans CV, Redmond N, Lin JS. Screening for peripheral artery disease using the ankle-brachial index: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(2):184\u201396.","journal-title":"JAMA"},{"issue":"10153","key":"2325_CR66","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S0140-6736(18)31650-7","volume":"392","author":"JW Olin","year":"2018","unstructured":"Olin JW, Halperin JL. US Preventive Services Task Force recommendation statement regarding screening for peripheral artery disease with the ankle-brachial index: d\u00e9j\u00e0 vu all over again. Lancet. 2018;392(10153):1160\u20132.","journal-title":"Lancet"},{"issue":"2","key":"2325_CR67","doi-asserted-by":"publisher","first-page":"e002407","DOI":"10.1136\/bmjdrc-2021-002407","volume":"9","author":"L Sprenger","year":"2021","unstructured":"Sprenger L, Mader A, Larcher B, M\u00e4chler M, Vonbank A, Zanolin-Purin D, et al. Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease. BMJ Open Diabetes Res Care. 2021;9(2):e002407.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"2325_CR68","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ejvs.2009.06.002","volume":"38","author":"AH Momsen","year":"2009","unstructured":"Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38(4):463\u201374.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"2325_CR69","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338\u201350.","journal-title":"Circulation"},{"issue":"20","key":"2325_CR70","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","volume":"141","author":"GG Schwartz","year":"2020","unstructured":"Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2020;141(20):1608\u201317.","journal-title":"Circulation"},{"issue":"21","key":"2325_CR71","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994\u20132004.","journal-title":"N Engl J Med"},{"issue":"14","key":"2325_CR72","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"2325_CR73","first-page":"21","volume":"6","author":"E Kaplovitch","year":"2021","unstructured":"Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021;6(1):21\u20139.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2325_CR74","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/jama.2013.280618","volume":"311","author":"M Ruiz-Canela","year":"2014","unstructured":"Ruiz-Canela M, Estruch R, Corella D, Salas-Salvad\u00f3 J, Mart\u00ednez-Gonz\u00e1lez MA. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA. 2014;311(4):415\u20137.","journal-title":"JAMA"},{"issue":"7258","key":"2325_CR75","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"25","key":"2325_CR76","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1016\/j.jacc.2018.09.078","volume":"72","author":"CC Low Wang","year":"2018","unstructured":"Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, et al. Cardiovascular and Limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID trial. J Am Coll Cardiol. 2018;72(25):3274\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2325_CR77","doi-asserted-by":"publisher","first-page":"e3627","DOI":"10.1002\/dmrr.3627","volume":"39","author":"P Caruso","year":"2023","unstructured":"Caruso P, Maiorino MI, Bellastella G, Esposito K, Giugliano D. Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope? Diabetes Metab Res Rev. 2023;39(7):e3627.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"2325_CR78","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1210\/jc.2014-2291","volume":"100","author":"M Rizzo","year":"2015","unstructured":"Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015;100(2):603\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2325_CR79","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","volume":"15","author":"M Rizzo","year":"2016","unstructured":"Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016;15(1):162.","journal-title":"Cardiovasc Diabetol"},{"key":"2325_CR80","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabres.2019.02.006","volume":"149","author":"AM Patti","year":"2019","unstructured":"Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, et al. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: an 8-month prospective study. Diabetes Res Clin Pract. 2019;149:163\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2325_CR81","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/jcm9040912","volume":"9","author":"AM Patti","year":"2020","unstructured":"Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes. J Clin Med. 2020;9(4):912.","journal-title":"J Clin Med"},{"issue":"9","key":"2325_CR82","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.3390\/ijms22094633","volume":"22","author":"RV Giglio","year":"2021","unstructured":"Giglio RV, Pantea Stoian A, Al-Rasadi K, Banach M, Patti AM, Ciaccio M, et al. Novel therapeutical approaches to managing atherosclerotic risk. Int J Mol Sci. 2021;22(9):4633.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2325_CR83","doi-asserted-by":"publisher","first-page":"e241545","DOI":"10.1001\/jamanetworkopen.2024.1545","volume":"7","author":"P Caruso","year":"2024","unstructured":"Caruso P, Maiorino MI, Longo M, Porcellini C, Matrone R, Digitale Selvaggio L, et al. Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the STARDUST randomized clinical trial. JAMA Netw Open. 2024;7(3):e241545.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2325_CR84","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","volume":"23","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2325_CR85","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12933-023-01754-2","volume":"22","author":"L Scisciola","year":"2023","unstructured":"Scisciola L, Taktaz F, Fontanella RA, Pesapane A, Surina, Cataldo V, et al. Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors. Cardiovasc Diabetol. 2023;22(1):24.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2325_CR86","first-page":"322","volume":"10","author":"B Rolek","year":"2023","unstructured":"Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, G\u0105secka A. SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain. J Cardiovasc Dev Dis. 2023;10(8):322.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"2325_CR87","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","volume":"34","author":"JA Sargeant","year":"2019","unstructured":"Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul). 2019;34(3):247\u201362.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"9131","key":"2325_CR88","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854\u201365.","journal-title":"Lancet"},{"issue":"6","key":"2325_CR89","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","volume":"169","author":"A Kooy","year":"2009","unstructured":"Kooy A, de Jager J, Lehert P, Bets D, Wulffel\u00e9 MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616\u201325.","journal-title":"Arch Intern Med"},{"key":"2325_CR90","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.avsg.2022.09.064","volume":"90","author":"S Tan","year":"2023","unstructured":"Tan S, Goudot G, Arnoux A, Tran Y, Maissoro H, Poenou G, et al. Occurrence of major local lower limb events in type 2 Diabetic patients with lower extremity arterial disease: impact of metformin. Ann Vasc Surg. 2023;90:153\u201361.","journal-title":"Ann Vasc Surg"},{"issue":"26","key":"2325_CR91","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehaa777","volume":"42","author":"G Ferrannini","year":"2021","unstructured":"Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J. 2021;42(26):2565\u201373.","journal-title":"Eur Heart J"},{"issue":"26","key":"2325_CR92","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1093\/eurheartj\/ehaa879","volume":"42","author":"N Sattar","year":"2021","unstructured":"Sattar N, McGuire DK. Prevention of CV outcomes in antihyperglycaemic drug-na\u00efve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J. 2021;42(26):2574\u20136.","journal-title":"Eur Heart J"},{"issue":"1","key":"2325_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-023-01789-5","volume":"22","author":"PC Tsai","year":"2023","unstructured":"Tsai PC, Chuang WJ, Ko AM, Chen JS, Chiu CH, Chen CH, et al. Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2023;22(1):57.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2325_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12933-023-01992-4","volume":"22","author":"M Takahara","year":"2023","unstructured":"Takahara M, Soga Y, Fujihara M, Iida O, Kawasaki D. Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease. Cardiovasc Diabetol. 2023;22(1):273.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2325_CR95","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2215\/CJN.0000000000000115","volume":"18","author":"EL Fu","year":"2023","unstructured":"Fu EL, D\u2019Andrea E, Wexler DJ, Patorno E, Paik JM. Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US Cohort Study. Clin J Am Soc Nephrol. 2023;18(5):592\u2013601.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"2325_CR96","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"10365","key":"2325_CR97","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"6\u20137","key":"2325_CR98","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.acvd.2023.04.002","volume":"116","author":"K Ba","year":"2023","unstructured":"Ba K, Sow MA, Magne J, Salle L, Lacroix P, Chastaingt L, et al. Risk of amputation under diuretics in patients with or at risk of lower extremity arterial disease: a systematic review and meta-analysis. Arch Cardiovasc Dis. 2023;116(6\u20137):357\u201363.","journal-title":"Arch Cardiovasc Dis"},{"issue":"9","key":"2325_CR99","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","volume":"64","author":"DS Lin","year":"2021","unstructured":"Lin DS, Lee JK, Chen WJ. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia. 2021;64(9):1949\u201362.","journal-title":"Diabetologia"},{"issue":"12","key":"2325_CR100","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s00125-022-05772-9","volume":"65","author":"DS Lin","year":"2022","unstructured":"Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chen WJ. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. Diabetologia. 2022;65(12):2032\u201343.","journal-title":"Diabetologia"},{"issue":"19","key":"2325_CR101","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"13","key":"2325_CR102","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"2325_CR103","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","volume":"22","author":"P Gourdy","year":"2023","unstructured":"Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22(1):79.","journal-title":"Cardiovasc Diabetol"},{"key":"2325_CR104","doi-asserted-by":"publisher","first-page":"109214","DOI":"10.1016\/j.diabres.2022.109214","volume":"184","author":"G Mahe","year":"2022","unstructured":"Mahe G, Brodmann M, Capodanno D, Ceriello A, Cuisset T, Delgado V, et al. Current management and screening of peripheral and coronary artery disease in people with diabetes mellitus in Europe. The PADDIA\/CADDIA survey. Diabetes Res Clin Pract. 2022;184:109214.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2325_CR105","doi-asserted-by":"publisher","first-page":"e00076","DOI":"10.1002\/edm2.76","volume":"2","author":"W Weng","year":"2019","unstructured":"Weng W, Tian Y, Kong SX, Ganguly R, Hersloev M, Brett J, et al. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. Endocrinol Diabetes Metab. 2019;2(3):e00076.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"2325_CR106","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20(1):154.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2325_CR107","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.amjmed.2018.07.006","volume":"131","author":"DG Hackam","year":"2018","unstructured":"Hackam DG, Vyas MV. Utilization of vasculoprotective therapy for peripheral artery disease: a systematic review and meta-analysis. Am J Med. 2018;131(11):1332\u2013e93.","journal-title":"Am J Med"},{"key":"2325_CR108","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.3402\/dfa.v1i0.5731","volume":"1","author":"A Nather","year":"2010","unstructured":"Nather A, Siok Bee C, Keng Lin W, Xin-Bei Valerie C, Liang S, Tambyah PA, et al. Value of team approach combined with clinical pathway for diabetic foot problems: a clinical evaluation. Diabet Foot Ankle. 2010;1:5731.","journal-title":"Diabet Foot Ankle"},{"issue":"1","key":"2325_CR109","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12902-016-0111-0","volume":"16","author":"C Wang","year":"2016","unstructured":"Wang C, Mai L, Yang C, Liu D, Sun K, Song W, et al. Reducing major lower extremity amputations after the introduction of a multidisciplinary team in patient with diabetes foot ulcer. BMC Endocr Disord. 2016;16(1):38.","journal-title":"BMC Endocr Disord"},{"issue":"2 Suppl","key":"2325_CR110","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.1016\/j.jvs.2015.10.003","volume":"63","author":"A Hingorani","year":"2016","unstructured":"Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: a clinical practice guideline by the society for vascular surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):s3\u201321.","journal-title":"J Vasc Surg"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T14:04:19Z","timestamp":1719410659000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02325-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GM reports consulting fees from Novartis and Amgen; honoraria for lectures and presentations from Amarin, Aspen, Bayer, BMS-Pfizer, Leo Pharma, and Perimed; and advisory board participation for Novo Nordisk and Sanofi. VA reports honoraria and institutional funding from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Organon, Novo Nordisk, and Vifor. EC declares consulting fees, honoraria for lectures, presentations, or speaker bureaus from Abbott, AlphaDiab, Ascencia, Lilly, LVL M\u00e9dical, Medtronic, MSD, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi-Aventis, as well as grants from AstraZeneca, LVL M\u00e9dical, and Roche Diagnostics outside the submitted work. KM reports consulting fees from Novo Nordisk; honoraria for lectures, presentations, or speaker bureaus from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, LifeScan, Abbott, and Bayer; and advisory board participation for Novo Nordisk, Sanofi, and Amarin. GSB reports honoraria for lectures, presentations, or speaker bureaus from Amgen, BMS, Leo Pharma, Novartis, Novo Nordisk, Pfizer, Sanofi, and Servier. DL reports honoraria for lectures, presentations, or speaker bureaus from Amgen, Aspen, Bayer, BMS, Leo Pharma, Pfizer, and Sanofi. TM reports receiving honoraria from Bayer, Incyte, Amarin, Novartis, and Novo Nordisk; and receiving non-financial support from Abbott, Alexion Pharma, Amgen, Bayer, Boehringer Ingelheim, BMS, Incyte, MSD, and Pfizer. PD reports consulting fees, honoraria for lectures, presentations, or speaker bureaus from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Sanofi, Abbott, MSD, and Bayer; and advisory board participation for Novo Nordisk, Eli Lilly, Menarini, and Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}